Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Matthew Wilson, MD BSc, MRCP, Catherine Ogilvie, MD, Jennifer Travers, MD, Michelle Martin, Jonathan Allan, Pam McKay, MD, Mike Leach, MD

Blood (2019) 134 (Supplement_1): 5285.

https://doi.org/10.1182/blood-2019-126704

Published: 2019

Journal Articles

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Holly Lee, MD, Lesley Street, MD, Jason Tay, MD, Jennifer Grossman, MD, John F Thaell, MD, Dawn Goodyear, MD, Sylvia McCulloch, MD, Peter Duggan, MD, Paola Neri, MD, Victor Jimenez-Zepeda, MD

Blood (2018) 132 (Supplement 1): 4495.

https://doi.org/10.1182/blood-2018-99-117819

Published: 2018

Journal Articles

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2018-99-119578

Published: 2018

Journal Articles

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Aaron Yarlas, PhD, Giampaolo Merlini, MD, Michelle K White, PhD, Asia Sikora Kessler, PhD, Andrew Lovley, MA, Spencer D Guthrie, MPH, MBA, Michael Pollock, Morie A. Gertz, MD

Blood (2018) 132 (Supplement 1): 4803.

https://doi.org/10.1182/blood-2018-99-119216

Published: 2018

Journal Articles

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Aneel Paulus, MD, Alak Manna, PhD, Sharoon Akhtar, MPhil, Neeraj Kumar Singh, B.Tech, Ansu Kumar, MS, Kabya Basu, MS, Akshita Trivedi, B.Tech, Debapriya Majumdar, M.Sc., Taher Abbasi, MS, MBA, Shireen Vali, PhD, Vivek Roy, MD, Peter Martin, FRCPC, MD MS, Morton Coleman, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD, Sikander Ailawadhi, Asher A. Chanan-Khan, MD

Blood (2017) 130 (Supplement 1): 1260.

https://doi.org/10.1182/blood.V130.Suppl_1.1260.1260

Published: 2017

Journal Articles

Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage

Blood (2016) 128 (22): 4627.

https://doi.org/10.1182/blood.V128.22.4627.4627

Published: 2016

Journal Articles

Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden

Blood (2016) 128 (22): 3273.

https://doi.org/10.1182/blood.V128.22.3273.3273

Published: 2016

Journal Articles

Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis

Blood (2016) 128 (22): 2082.

https://doi.org/10.1182/blood.V128.22.2082.2082

Published: 2016

Journal Articles

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Stefan O Schonland, MD, Tilmann Bochtler, MD, Axel Benner, Marianne Gawlik, Christoph Kimmich, Arnt V Kristen, Jörg Beimler, Anthony D. Ho, MD, Ute Hegenbart, MD

Blood (2013) 122 (21): 1993.

https://doi.org/10.1182/blood.V122.21.1993.1993

Published: 2013

Journal Articles

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Shameem Mahmood, MRCP. FRCPath, Sajitha Sachchithanantham, MRCP. FRCPath, Frank Bridoux, Thirusha Lane, RN, Lisa Rannigan, RN, Darren Foard, RN, Rabya Sayed, MRCP, Ketna Patel, MRCP, Marianna Fontanna, MD, Carol Whelan, MD, Helen J Lachmann, MD, FRCP, Julian D Gillmore, MD, Philip N Hawkins, MD, Ashutosh Wechalekar, MD FRCPath

Blood (2013) 122 (21): 3143.

https://doi.org/10.1182/blood.V122.21.3143.3143

Published: 2013

Journal Articles

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Dina Brauneis, ANP, Karen Quillen, MD, MPH, Nancy T Andrea, MD, John Mark Sloan, MD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 2019.

https://doi.org/10.1182/blood.V120.21.2019.2019

Published: 2012

Journal Articles

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Vaishali Sanchorawala, MD, David C. Seldin, MD, PhD, John Mark Sloan, MD, John L. Berk, MD, Martha Skinner

Blood (2009) 114 (22): 1883.

https://doi.org/10.1182/blood.V114.22.1883.1883

Published: 2009

Journal Articles

Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib.

Jeffrey A Steinberg, Jing Shen, Eric Sanchez, Haiming Chen, MD, PhD, Zhi-Wei Li, PhD, Jacqueline Hilger, MS, James R. Berenson, MD

Blood (2009) 114 (22): 3832.

https://doi.org/10.1182/blood.V114.22.3832.3832

Published: 2009

Journal Articles

Feasibility and Efficacy of Autologous Stem Cell Transplantation as First-Line Therapy for Peripheral T-Cell Lymphoma: a Single Center Experience

Lorenzo Falchi, Marco Gunnellini, Monica Schippa, Chiara Listorti, Marta Gubbiotti, Rita Emili, Anna Marina Liberati

Blood (2008) 112 (11): 4441.

https://doi.org/10.1182/blood.V112.11.4441.4441

Published: 2008

Journal Articles

Autologous Stem Cell Transplantation in Patients with Autonomic Neuropathy Due to AL Amyloidosis

David Dingli, Shaji K. Kumar, Francis K. Buadi, Angela Dispenzieri, Suzanne R. Hayman, Martha Q. Lacy, Dennis A. Gastineau, Mark R. Litzow, Morie A. Gertz

Blood (2008) 112 (11): 3318.

https://doi.org/10.1182/blood.V112.11.3318.3318

Published: 2008

Journal Articles

Incidence, Predictors, and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma

Hatoon Ezzat, MD, Matthew C Cheung, MD, SM, Lisa K Hicks, MD, MSc, Kevin C Murphy, MD, Chantal S Leger, MD, Linda R Taggart, MD, Jordana Boro, Julio SG Montaner, MD, Marianne Harris, MD, Linda M Vickars, MD, Heather A Leitch, MD, PhD

Blood (2008) 112 (11): 2587.

https://doi.org/10.1182/blood.V112.11.2587.2587

Published: 2008

Journal Articles

A Profile of 44 Long Term Survivors (>10yrs) with AL Amyloidosis.

Ashutosh D. Wechalekar, MD, Helen J. Lachmann, MD, Julian D. Gillmore, MD, PhD, Philip N. Hawkins, PhD, FRCP

Blood (2007) 110 (11): 4765.

https://doi.org/10.1182/blood.V110.11.4765.4765

Published: 2007

Journal Articles

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Michalis Michail, MD, Efstathios Kastritis, MD, Sossana Delimpassi, MD, Marie Christine Kyrtsonis, MD, Evridiki Michali, MD, Nicolaos Anagnostopoulos, MD, Konstantinos Zervas, MD, Eirini Katodritou, MD, Panagiotis Panagiotidis, MD, Natalia Tzenou, Gerassimos Pangalis, MD, Meletios Athanasios Dimopoulos, MD

Blood (2007) 110 (11): 4729.

https://doi.org/10.1182/blood.V110.11.4729.4729

Published: 2007

Journal Articles

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Raymond Comenzo, MD, Hani Hassoun, MD, Lilian Reich, MD, Nancy Collins, PhD, Andre Nuta, Xiaoshe Chen, PhD, Ping Zhou, MD. PhD, Bradly Clark, MD, Julie Teruya-Feldstein, MD, Martin Fleisher, PhD, David Wuest, MD, Stephen D. Nimer, MD

Blood (2006) 108 (11): 3087.

https://doi.org/10.1182/blood.V108.11.3087.3087

Published: 2006

NARROW

ACOPP Chemotherapy for Frontline Treatment of Older Patients with Hodgkin Lymphoma - a Pilot Study

Monoclonal Gammopathy of Clinical Significance - a Single Center Experience

Impact of Inotersen on Functioning and Activities of Daily Living for Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

Impact of Inotersen on Subgroups of Patients with Hereditary TTR Amyloidosis: Results from a Double-Blind Placebo-Controlled Trial

The Oral Proteasome Inhibitor Ixazomib, Alone and in Combination with Ibrutinib, Induces Lethality in Waldenstrom Macroglobulinemia Cells That Are Resistant to Ibrutinib

Effect of Standard Dose Versus Risk Adapted Melphalan Conditioning on Outcomes in Systemic AL Amyloidosis Patients Undergoing Frontline Autologous Stem Cell Transplant Based on Revised Mayo Stage

Thyroid Functional Abnormalities in Newly Diagnosed AL Amyloidosis: Frequency and Influence By Type of Organ Involvement and Disease Burden

Predictors of Early Relapse Following Initial Therapy for Systemic Immunoglobulin Light Chain Amyloidosis

Lenalidomide/Melphalan / Dexamethasone Chemotherapy In 50 Patients With Newly Diagnosed Amyloid Light Chain Amyloidosis: First Results Of a Prospective Single Center Phase 2 Study (Leomex)

Risk Of Progression Of Localised Amyloidosis To Systemic Disease In 606 Patients Over 30 Years

Treatment of AL Amyloidosis with Two Cycles of Induction Therapy with Bortezomib and Dexamethasone Followed by Bortezomib-High Dose Melphalan Conditioning and Autologous Stem Cell Transplantation

Oral Cyclic Melphalan and Dexamethasone in the Treatment of Patients with AL Amyloidosis; Ineligible for High-Dose Melphalan and Stem Cell Transplantation.

Alpha Lipoic Acid (ALA) Inhibits the Anti-Myeloma Effects of Bortezomib.

Feasibility and Efficacy of Autologous Stem Cell Transplantation as First-Line Therapy for Peripheral T-Cell Lymphoma: a Single Center Experience

Autologous Stem Cell Transplantation in Patients with Autonomic Neuropathy Due to AL Amyloidosis

Incidence, Predictors, and Significance of Severe Toxicity in Patients with HIV-Associated Hodgkin Lymphoma

A Profile of 44 Long Term Survivors (>10yrs) with AL Amyloidosis.

Clinical Characteristics and Outcome of Primary AL Amyloidosis in Greece.

Mobilization of Blood Stem Cells with G-CSF in Systemic Light-Chain Amyloidosis: Dominant Organ Involvement Significantly Affects Stem Cell Collection.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only